Industry pays attention to AZ’s Symbicort Rapihaler
AstraZeneca Korea’s ‘Symbicort Rapihaler’ which strengthened its inhaler portfolio has attracted interests of the industry.
AstraZeneca Korea introduced ‘Symbicort Rapihaler’ through a press conference on the 18th, and announced to extent the pipeline, such as new drug development and investmen...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
